Literature DB >> 19821525

Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study.

Robert P Myers1, Abdel Aziz M Shaheen, Andrew Fong, Kelly W Burak, Alex Wan, Mark G Swain, Robert J Hilsden, Lloyd Sutherland, Hude Quan.   

Abstract

UNLABELLED: The recent epidemiology and outcomes of primary biliary cirrhosis (PBC) in North America are incompletely described, partly due to difficulties in case ascertainment. In light of their availability, broad coverage, and limited expense, administrative databases may facilitate such investigations. We used population-based administrative data (inpatient, ambulatory care, and physician billing databases) and a validated International Classification of Diseases coding algorithm to describe the epidemiology and natural history of PBC in the Calgary Health Region (population approximately 1.1 million). Between 1996 and 2002, the overall age/sex-adjusted annual incidence of PBC was 30.3 cases per million (48.4 per million in women, 10.4 per million in men). Although the incidence remained stable, the prevalence increased from 100 per million in 1996 to 227 per million in 2002 (P < 0.0005). Among 137 incident cases with a total follow-up of 801 person-years from diagnosis (median 5.8 years), 27 patients (20%) died and six (4.4%) underwent liver transplantation. The estimated 10-year probabilities of survival, liver transplantation, and transplant-free survival were 73% (95% confidence interval [CI] 60%-83%), 6% (95% CI 2.5%-12.6%), and 68% (95% CI 55%-78%), respectively. Survival in PBC patients was significantly lower than that of the age/sex-matched Canadian population (standardized mortality ratio 2.87; 95% CI 1.89-4.17); male sex (hazard ratio [HR] 3.80; 95% CI 1.85-7.82) and an older age at diagnosis (HR per additional year, 1.06; 95% CI 1.03-1.10) were independent predictors of mortality.
CONCLUSION: This population-based study demonstrates that the burden of PBC in Canada is high and growing. Survival of PBC patients is significantly lower than that of the general population, emphasizing the importance of developing new therapies for this condition.

Entities:  

Mesh:

Year:  2009        PMID: 19821525     DOI: 10.1002/hep.23210

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  37 in total

Review 1.  Current and Future Burden of Chronic Nonmalignant Liver Disease.

Authors:  Prowpanga Udompap; Donghee Kim; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-17       Impact factor: 11.382

2.  Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis.

Authors:  L M Stinton; M Swain; R P Myers; A A Shaheen; M J Fritzler
Journal:  Clin Exp Immunol       Date:  2010-11-22       Impact factor: 4.330

3.  Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis.

Authors:  Na Zeng; Weijia Duan; Sha Chen; Shanshan Wu; Hong Ma; Xiaojuan Ou; Hong You; Yuanyuan Kong; Jidong Jia
Journal:  Hepatol Int       Date:  2019-09-25       Impact factor: 6.047

4.  Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland.

Authors:  Benedetta Terziroli Beretta-Piccoli; Guido Stirnimann; Andreas Cerny; David Semela; Roxane Hessler; Beat Helbling; Felix Stickel; Carolina Kalid-de Bakker; Florian Bihl; Emiliano Giostra; Magdalena Filipowicz Sinnreich; Carl Oneta; Adriana Baserga; Pietro Invernizzi; Marco Carbone; Joachim Mertens
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 5.  Xenobiotics and loss of tolerance in primary biliary cholangitis.

Authors:  Jinjun Wang; Guoxiang Yang; Alana Mari Dubrovsky; Jinjung Choi; Patrick S C Leung
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

6.  Risk factors for mortality in patients with alcoholic hepatitis and assessment of prognostic models: A population-based study.

Authors:  Jack X Q Pang; Erin Ross; Meredith A Borman; Scott Zimmer; Gilaad G Kaplan; Steven J Heitman; Mark G Swain; Kelly Burak; Hude Quan; Robert P Myers
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04

7.  The feasibility and reliability of transient elastography using Fibroscan®: a practice audit of 2335 examinations.

Authors:  Jack X Q Pang; Faruq Pradhan; Scott Zimmer; Sophia Niu; Pam Crotty; Jenna Tracey; Christopher Schneider; Steven J Heitman; Gilaad G Kaplan; Mark G Swain; Robert P Myers
Journal:  Can J Gastroenterol Hepatol       Date:  2014-03

Review 8.  Primary biliary cholangitis: a comprehensive overview.

Authors:  Ana Lleo; Simona Marzorati; Juan-Manuel Anaya; M Eric Gershwin
Journal:  Hepatol Int       Date:  2017-11-21       Impact factor: 6.047

9.  Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China.

Authors:  Haiying Liu; Yunfeng Liu; Luxia Wang; Dexing Xu; Bingliang Lin; Renqian Zhong; Sitang Gong; Mauro Podda; Pietro Invernizzi
Journal:  BMC Gastroenterol       Date:  2010-09-03       Impact factor: 3.067

10.  Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA.

Authors:  Patrick S C Leung; Jinjun Wang; Phornnop Naiyanetr; Thomas P Kenny; Kit S Lam; Mark J Kurth; M Eric Gershwin
Journal:  J Autoimmun       Date:  2013-01-24       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.